AUTL News and Press, Autolus Therapeutics plc From 01/22/24

PDUFA Goal date is November 16, 2024 Company on track to submit a marketing authorization application to the European Medicines Agency (EMA) in the first half of 2024 LONDON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharma...

LONDON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Robert W. Azelby to the Board of Directors. Mr. Azelby brings more than 30 ...

2023-12-22 07:21:29 ET More on Autolus Therapeutics Autolus Therapeutics: Pivotal Trial Using Familiar Approach, Possible Approval Coming Fast Seeking Alpha’s Quant Rating on Autolus Therapeutics Historical earnings data for Autolus Therapeutics For fu...

-  Appointment of Elisabeth (“Lis”) Leiderman, M.D. -  Resignation of Kapil Dhingra, M.D. LONDON, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell...

2023-12-18 04:12:40 ET Summary Autolus Therapeutics is developing cell-based immunotherapy for cancer, focusing on CD19 in ALL. Their flagship product, obe-cel, has shown promising results in treating relapsed/refractory B-cell ALL with reduced toxicities compared to other CAR T-c...

Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall immunotoxicity across all cohorts in r/r B-ALL, and particularly in patients with low leukemic burden at lymphodepletion Longer-term data from a pooled analysis from the ALLCAR19 study ...

BLA submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) Company on track to submit a marketing authorization application to the European Medicines Agency (EMA) in the first half of 2...

Shares of Autolus Therapeutics PLC (NASDAQ: AUTL) traded at a new 52-week high today and are currently trading at $2.73. So far today, approximately 676.5k shares have been exchanged, as compared to an average 30-day volume of 328.27k shares. Autolus Therapeutics PLC, a clinical-stage biophar...

2023-11-15 17:30:35 ET Gainers Veeco Instruments  ( VECO ) +5% . Humacyte ( HUMA ) +5% . Expensify ( EXFY ) +5% . ContextLogic ( WISH ) +4% . Tetra Tech ( TTEK ) +4% . Losers: Cisco Systems ( CSCO ) -11% . ...

In-person and webcast event on Sunday, 10 December, 2023 at 8:00 AM PT / 4:00 PM GMT Review of pooled analysis of the ongoing FELIX Phase Ib/II study, pooled analysis from ALLCAR19 and FELIX Phase Ib studies and ALLCAR19 extension with obe-cel, as well as initial data from the AUTO8 M...